Figure 3:

Genome-based approach to lung cancer. In the current era of genomic medicine, mutation testing of the tumor plays an important role in identifying the patients with targetable abnormalities with effective agents and optimizing therapeutic approach in advanced NSCLC. (The algorithm is based on National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer, version 3.2012 [113]). * = If EGFR mutation is discovered prior to first-line chemotherapy, erlotinib is recommended. If EGFR mutation is discovered during first-line chemotherapy, switching to maintenance erlotinib or the addition of erlotinib to current chemotherapy is recommended (113). ALK = anaplastic lymphoma kinase, NOS = not otherwise specified.